Effectiveness of CBD for Neuropathic Pain in Diabetic Foot Neuropathy

Universidad Complutense de Madrid

Status: Completed

Conditions: Neuropathic Pain Associated With Diabetic Peripheral Neuropathy; Xerosis Cutis

Treatments: Drug: Group 2. Cannabidiol and Urea 10% formula.; Drug: Group 3. Placebo formula.; Drug: Group 1. Complete formula

Study type: Interventional

Funder types: Other

Identifiers

NCT07162454

24/193-EC_X

Details and patient eligibility

About

Evaluation of cannabidiol and urea 10%.

Full description

This study evaluated the impact of cannabidiol on neuropathic pain and the action of urea 10% on skin quality in patients with diabetic foot syndrome and diabetic neuropathy.

Enrollment: 23 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients all biological sexes
• Patients of legal age (18 years).
• Patients without cognitive impairment
• Patients Diagnosed with diabetic neuropathy,
• Patients who were able to complete the neuropathic pain scale autonomously, cooperatively and independently.

Exclusion criteria

• Patients who declined participation
• Patients with critical ischaemia and
• Patients with a history of allergy or hypersensitivity to any of the components of the cream were excluded from the study.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Triple Blind

---

23 participants in 3 patient groups, including a placebo group

Group 1. Complete formula.

Experimental group

Description:

Participants in this group received a cream with cannabidiol, urea 10%, arnica and menthol as active ingredients during 1 month.

Treatment:

Drug: Group 1. Complete formula

Group 2. Cannabidiol and Urea 10% formula.

Experimental group

Description:

Participants in this group received a cream with cannabidiol, urea 10% as active ingredients during 1 month.

Treatment:

Drug: Group 2. Cannabidiol and Urea 10% formula.

Group 3. Base formula.

Placebo Comparator group

Description:

Participants in this group received a base cream with no active ingredients.

Treatment:

Drug: Group 3. Placebo formula.